Danone 2023 Profit Fell; 2024 Guidance in Line With Midterm Targets
By Kimberley Kao
Danone reported a fall in full-year profit and sales while saying guidance for 2024 remains in line with its mid-term targets.
The French food company said Thursday that 2023 net profit was 881 million euros ($953.1 million) compared with EUR959 million in the previous year. Recurring net income, which excludes exceptional items, was EUR2.28 billion, up 3.5% compared with the same period a year earlier.
The recurring operating margin for the year was 12.6%, up 40 basis points compared with the previous year, with gains in volume, mix and price partially offset by input-cost inflation net of productivity, the company said.
Full-year sales was EUR27.62 billion, down from EUR27.66 billion in 2022. On a like-for-like basis, sales rose 7.0%, with price up 7.4% and volume/mix down 0.4%.
In the fourth quarter, consolidated sales were EUR6.66 billion, down from EUR7.01 billion a year ago.
Danone said its 2024 guidance was in line with its mid-term ambitions, with like-for-like sales growth expected between 3% and 5%, and recurring operating margin expected to post moderate improvement.
The board of directors will propose a dividend of EUR2.10 a share for 2023, up 5.0% from the previous year.
Write to Kimberley Kao at kimberley.kao@wsj.com
(END) Dow Jones Newswires
February 22, 2024 01:42 ET (06:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks